EBIDTA fell by 16% YoY to Rs 61.7 crore while EBIDTA margin contracted by 610 bps to 15% during the quarter.

Operating profit in Q3 FY23 stood at Rs 57.3 crore, down by 15% from Rs 67.5 crore in Q3 FY22.

Aditi Panandikar, managing director, Indoco Remedies, said, “A good performance in domestic business and an excellent growth in export business has allowed us to post good results this quarter.”

Indoco Remedies, headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries.